Drug innovation will spur Pfizer’s dividend

PFIZER INC. $42 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.8 billion; Market cap: $243.6 billion; Dividend yield: 3.4%; Dividend Sustainability Rating: Highest; www.pfizer.com) is one of the world’s leading prescription drugmakers. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia)… Read More

Spinoff plans enhance their prospects

GENERAL ELECTRIC CO. $8.98 (New York symbol GE, Manufacturing & Industry sector; Shares outstanding: 8.7 billion; Market cap: $78.1 billion; Dividend yield: 0.5%; Takeover Target Rating: Medium; www.ge.com) recently announced a major restructuring that will narrow its focus to three main businesses: aviation operations (jet engines and aircraft… Read More

Dividend Advisor Hotline – Friday, January 4, 2019

PFIZER INC., $43.00, New York symbol PFE, is one of the world’s largest makers of prescription drugs. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia) and Enbrel (rheumatoid arthritis).

Starting with the March 2019 payment, Pfizer will increase its quarterly dividend by 5.9%,… Read More

Pfizer lifts value for shareholders

PFIZER INC. $42 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.8 billion; Market cap: $243.6 billion; Price-to-sales ratio: 4.6; Dividend yield: 3.4%; TSINetwork Rating: Above Average; www.pfizer.com) is one of the world’s largest makers of prescription drugs. Its top-selling brands include Lyrica… Read More

We make an exception for Pfizer

We generally recommend investors avoid pharmaceutical companies due to the huge costs and risks of developing new drugs.
However, Pfizer is an exception. We feel its large size makes it less dependent on the success or failure of any single drug. In addition, the stock has… Read More

Second spinoff set to unlock value

Pfizer’s shares have gained 50% in the five years since it used an initial public offering to set up its animal-drug business as Zoetis. It then offered its remaining shares to investors. The new company now plans to sell or spin off its consumer business,… Read More